

Killenaule Pharmacy Ltd
Abridged Unaudited Financial Statements
for the financial year to cessation on 31 March 2025

Killenaule Pharmacy Ltd
CONTENTS

	Page
Directors' Responsibilities Statement	3
Balance Sheet	4
Reconciliation of Shareholders' Funds	5
Notes to the Financial Statements	6 - 8

Killenaule Pharmacy Ltd

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year to cessation on 31 March 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently.
- make judgements and accounting estimates that are reasonable and prudent.
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Tadhg Gleeson
Director

28 December 2025

Jack O Keeffe
Director

28 December 2025

Killenaule Pharmacy Ltd

BALANCE SHEET

as at 31 March 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	5	-	1
Current Assets			
Cash and cash equivalents		-	50,890
Creditors: amounts falling due within one year	7	(70,714)	(121,598)
Net Current Liabilities		(70,714)	(70,708)
Total Assets less Current Liabilities		(70,714)	(70,707)
Capital and Reserves			
Called up share capital presented as equity		4	4
Retained earnings		(70,718)	(70,711)
Equity attributable to owners of the company		(70,714)	(70,707)

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Killenaule Pharmacy Ltd, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 28 December 2025 and signed on its behalf by:

Tadhg Gleeson
Director

Jack O Keeffe
Director

Killenaule Pharmacy Ltd
RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 31 March 2025

	Called up share capital €	Retained earnings €	Total €
At 1 April 2023	4	(70,692)	(70,688)
Loss for the financial year	-	(19)	(19)
At 31 March 2024	4	(70,711)	(70,707)
Loss for the financial year	-	(7)	(7)
At 31 March 2025	4	(70,718)	(70,714)

Killenaule Pharmacy Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year to cessation on 31 March 2025

1. General Information

Killenaule Pharmacy Ltd is a company limited by shares incorporated in Ireland. The registered office of the company is Academy House, Fethard, Co Tipperary. The Company has ceased trading and is being seeking to be struck off having no assets or liabilities in excess of €150. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Plant and machinery	- 15% Straight line
---------------------	---------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company does not operate any pension schemes and currently has no employees other than the Company Directors.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

Killenaule Pharmacy Ltd
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year to cessation on 31 March 2025

3. Operating loss	2025 €	2024 €
Operating loss is stated after charging:		
Loss/(profit) on disposal of tangible assets	1	-
	<u>1</u>	<u>-</u>
 4. Employees		
The average monthly number of employees, including directors, during the financial year was 2, (2024 - 2).		
	2025 Number	2024 Number
Directors	2	2
	<u>2</u>	<u>2</u>
 5. Tangible assets		
	Plant and machinery	Total
	€	€
Cost		
At 1 April 2024	1	1
Disposals	(1)	(1)
	<u>-</u>	<u>-</u>
At 31 March 2025	-	-
	<u>-</u>	<u>-</u>
Depreciation		
At 1 April 2024	-	-
	<u>-</u>	<u>-</u>
At 31 March 2025	-	-
	<u>-</u>	<u>-</u>
Net book value		
At 31 March 2025	-	-
	<u>-</u>	<u>-</u>
At 31 March 2024	1	1
	<u>1</u>	<u>1</u>
 6. Investments		
		Other unlisted investments €
Investments Cost		
At 31 March 2025		591,478
		<u>591,478</u>
Provision for diminution in value:		
At 31 March 2025		591,478
		<u>591,478</u>
Net book value		
At 31 March 2025		-
		<u>-</u>
In the view of the Directors the realizable value of the Company's investments are expected to be Nil as at 31 Mar 2023.		
7. Creditors	2025 €	2024 €
Amounts falling due within one year		
Directors' current accounts (Note 10)	70,714	121,598
	<u>70,714</u>	<u>121,598</u>

Killenaule Pharmacy Ltd
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year to cessation on 31 March 2025

8. Income Statement

	2025	2024
	€	€
At 1 April 2024	(70,711)	(70,692)
Loss for the financial year	(7)	(19)
At 31 March 2025	(70,718)	(70,711)

9. Capital commitments

The company had no material capital commitments at the financial year-ended 31 March 2025.

10. Directors' transactions

The following amounts are repayable to the directors:

	2025	2024
	€	€
Tadhg Gleeson	52,787	103,671
Jack O Keeffe	17,927	17,927
	70,714	121,598

Loans advanced by the Directors to the Companies have been made available on an interest free basis and will remain in place to support the Company.

11. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

12. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 28 December 2025.